BioSpace News Archive

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal first quarter 2022 financial results after the market closes on Monday, November 8, 2021.

Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8,

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2021.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” in the past year.

Protara Therapeutics, Inc., a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protara’s new General Counsel.

Geron Corporation announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway launched in the United Kingdom by the Medicines and Healthcare products Regulatory Agency in January 2021, post-Brexit.

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call.

Angel Pharmaceuticals Co., Ltd. announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation to initiate clinical trials in patients with relapsed/refractory T-cell lymphomas in China.

Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard, with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer compared to annual fecal immunochemical test, when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population.

NeuroTrauma Sciences, LLC announced that it has awarded a grant to Jonathan Lifshitz, PhD, professor at the University of Arizona College of Medicine – Phoenix who leads the Neurotrauma & Social Impact research team, to conduct preclinical research on its novel neuroprotective compound NTS-104 in mild traumatic brain injury, with a focus on addressing clinically-relevant outcome measures such as anxiety, depression, cognitive dysfunction, and sleep-wake disturbances.